Edwards Lifesciences (EW) and Bionik Laboratories (BNKL) Critical Survey

Edwards Lifesciences (NYSE:EW) and Bionik Laboratories (OTCMKTS:BNKL) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Profitability

This table compares Edwards Lifesciences and Bionik Laboratories’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Edwards Lifesciences 20.67% 30.11% 16.54%
Bionik Laboratories -782.97% -69.15% -53.86%

Earnings and Valuation

This table compares Edwards Lifesciences and Bionik Laboratories’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Edwards Lifesciences $3.44 billion 9.30 $583.60 million $3.80 40.21
Bionik Laboratories $990,000.00 18.82 -$14.62 million N/A N/A

Edwards Lifesciences has higher revenue and earnings than Bionik Laboratories.

Volatility and Risk

Edwards Lifesciences has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Bionik Laboratories has a beta of -1.18, meaning that its share price is 218% less volatile than the S&P 500.

Institutional and Insider Ownership

82.3% of Edwards Lifesciences shares are owned by institutional investors. 1.8% of Edwards Lifesciences shares are owned by company insiders. Comparatively, 45.0% of Bionik Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Edwards Lifesciences and Bionik Laboratories, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edwards Lifesciences 2 7 12 0 2.48
Bionik Laboratories 0 0 0 0 N/A

Edwards Lifesciences presently has a consensus target price of $164.25, suggesting a potential upside of 7.49%. Given Edwards Lifesciences’ higher possible upside, analysts clearly believe Edwards Lifesciences is more favorable than Bionik Laboratories.

Summary

Edwards Lifesciences beats Bionik Laboratories on 9 of the 11 factors compared between the two stocks.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings and the beating-heart mitral repair systems; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

About Bionik Laboratories

Bionik Laboratories Corp., a robotics company, focuses on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The company specializes in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion Systems, which include the InMotion ARM that allows clinicians to deliver sensor motor therapy to the shoulder and elbow to develop new neural pathways; InMotion ARM/HAND, an add-on module to be used with the InMotion ARM; and InMotion WRIST, a rehabilitation device that enables clinicians to deliver optimum intensive sensor motor wrist and forearm therapy to patients with neurological conditions. The company is also developing InMotion HOME, an upper extremity product that allows patients to extend their therapy for as long as needed while rehabilitating at home; and ARKE, a robotic lower body exoskeleton designed for wheelchair bound individuals suffering from spinal cord injuries, stroke, and other mobility disabilities. Bionik Laboratories Corp. was founded in 2010 and is headquartered in Toronto, Canada.

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply